Format

Send to

Choose Destination
Mult Scler. 2015 Feb;21(2):163-70. doi: 10.1177/1352458514538110. Epub 2014 Jun 16.

Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria.

Author information

1
Neuroimmunology and MS Research Section, University Hospital Zurich, Switzerland.
2
MS Centre Amsterdam, VU University Medical Centre, The Netherlands.
3
University of Calgary, Canada.
4
Medical Faculty, Heinrich-Heine University Düsseldorf, Germany.
5
New York University School of Medicine, New York, USA.
6
Johns Hopkins Hospital, Baltimore, MD, USA.
7
University of Copenhagen, Denmark.
8
University of Texas Southwestern Medical Center at Dallas, USA.
9
MS Center, University of California San Francisco, USA.
10
Save Sight Institute, University of Sydney, Australia.
11
University of Lille Nord de France, France.
12
NeuroCure Clinical Research Center (NCRC) and Clinical and Experimental MS Research Center, Charite, Universitätsmedizin Berlin, Germany.
13
Moorfields Eye Hospital, The National Hospital for Neurology and Neurosurgery and St. Thomas' Hospital, London, UK.
14
University Hospital Zurich, Switzerland.
15
Center for Neuroimmunology, Institute of Biomedical Research August, Pi Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain.
16
Bern University Hospital and University of Bern, Switzerland.
17
MS Centre Amsterdam, VU University Medical Centre, The Netherlands a.petzold@vumc.nl.

Abstract

BACKGROUND:

Retinal optical coherence tomography (OCT) permits quantification of retinal layer atrophy relevant to assessment of neurodegeneration in multiple sclerosis (MS). Measurement artefacts may limit the use of OCT to MS research.

OBJECTIVE:

An expert task force convened with the aim to provide guidance on the use of validated quality control (QC) criteria for the use of OCT in MS research and clinical trials.

METHODS:

A prospective multi-centre (n = 13) study. Peripapillary ring scan QC rating of an OCT training set (n = 50) was followed by a test set (n = 50). Inter-rater agreement was calculated using kappa statistics. Results were discussed at a round table after the assessment had taken place.

RESULTS:

The inter-rater QC agreement was substantial (kappa = 0.7). Disagreement was found highest for judging signal strength (kappa = 0.40). Future steps to resolve these issues were discussed.

CONCLUSION:

Substantial agreement for QC assessment was achieved with aid of the OSCAR-IB criteria. The task force has developed a website for free online training and QC certification. The criteria may prove useful for future research and trials in MS using OCT as a secondary outcome measure in a multi-centre setting.

KEYWORDS:

Atrophy; multiple sclerosis; outcome measurement; progressive

PMID:
24948688
DOI:
10.1177/1352458514538110
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center